Drugs / JNJ-90189892
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06651229 | Mar 2025 → Aug 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-90189892 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06651229 ↗ |